Next Article in Journal
Synthesis, Biological Evaluation, and Modeling of Dimeric PPI Analogues as Novel DNA Minor Groove Binders
Next Article in Special Issue
Polyanionic Drugs and Viral Oncogenesis: a Novel Approach to Control Infection, Tumor-associated Inflammation and Angiogenesis
Previous Article in Journal
Neglschisandrins C-D: Two New Dibenzocyclooctadiene Lignans from Schisandra neglecta
Previous Article in Special Issue
Progress in Drug Delivery to the Central Nervous System by the Prodrug Approach
Molecules 2008, 13(5), 1156-1178; doi:10.3390/molecules13051156

Prodrugs in Cardiovascular Therapy

1,3, 4,5 and 1,2,3,*
Received: 5 February 2008 / Revised: 14 May 2008 / Accepted: 14 May 2008 / Published: 14 May 2008
(This article belongs to the collection Prodrugs)
Download PDF [423 KB, uploaded 18 June 2014]
Abstract: Prodrugs are biologically inactive derivatives of an active drug intended to solve certain problems of the parent drug such as toxicity, instability, minimal solubility and non-targeting capabilities. The majority of drugs for cardiovascular diseases undergo firstpass metabolism, resulting in drug inactivation and generation of toxic metabolites, which makes them appealing targets for prodrug design. Since prodrugs undergo a chemical reaction to form the parent drug once inside the body, this makes them very effective in controlling the release of a variety of compounds to the targeted site. This review will provide the reader with an insight on the latest developments of prodrugs that are available for treating a variety of cardiovascular diseases. In addition, we will focus on several drug delivery methodologies that have merged with the prodrug approach to provide enhanced target specificity and controlled drug release with minimal side effects.
Keywords: Prodrug; cardiovascular disease; drug-eluting stents; antiplatelet; antithrombin. Prodrug; cardiovascular disease; drug-eluting stents; antiplatelet; antithrombin.
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |

MDPI and ACS Style

Sandros, M.G.; Sarraf, C.B.; Tabrizian, M. Prodrugs in Cardiovascular Therapy. Molecules 2008, 13, 1156-1178.

AMA Style

Sandros MG, Sarraf CB, Tabrizian M. Prodrugs in Cardiovascular Therapy. Molecules. 2008; 13(5):1156-1178.

Chicago/Turabian Style

Sandros, Marinella G.; Sarraf, Chady B.; Tabrizian, Maryam. 2008. "Prodrugs in Cardiovascular Therapy." Molecules 13, no. 5: 1156-1178.

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert